Stein=melanoma=it probably works
I copied the 43 page pdf of the 10K report (available on the online voting proxy page) and have so far read the introductory science part pages 1-5. While it is not easy reading, I do recommend it for those up to the task on this very hot day. This seems to me to be no cut and paste job but rather a well-written, up to date summary of the the basic science and where we stand on the various projects. It is good to know the company has somebody who can communicate this difficult material in a professional manner. There could be news in this summary but at the very least, it clarifies for me several matters. While I might not be the most appropriate person to pass on this information, I will try now. (Some is my interpretation, obviously).
1. Against bacteria, apparently the company is not using the ssDNA per se but rather a different approach to silence bacterial genes. This is "a separate technology against bacteria using mimetic oligonucleotides as sequences to silence targeted bacterial genes" (p.2 bottom).
2. The key problem to date has been to deliver enough of the "stuff". "[D]elivery methods have failed to provide sufficient quantities to be therapeuticaly effective..." (p. 2). Our technology is very promising for overcoming this problem. "Laboratory cell culture studies have demonstrated that the Company's ssDNA expression vector can adequately deliver sequence specific DNA molecules in sufficient quantities in virtually all cell types....The company has extended the results achieved in cell cultures to cells in live animals" (p. 2).
3. The herpes product would most likely be used for prevention and for babies (p. 3).
4. One of the possible uses for the anti-inflammatory topical product would be "joint swelling" (p. 3). To me, this sounds like arthritis. Move over Jointritis. This raises the possibility that our topical anti-inflammatory product MIGHT, after all, provide some alternative to NSAIDs (like Celebrex, Vioxx, Motrin) for localized pain - potentially important due to the growing concern about heart-related damage from NSAIDs with continuous use.
5. Until this publication, the company has been very careful abou the claims it makes about the effectiveness of this synthetic DNA plasmid product. They have always stated that they believe it to be AS effective as the older type but have raised the possibility that it might be MORE effective. While that care continues, this document reveals for the first time what might be the possible effectiveness benefit. "Our experiments have shown that the biological response to c-DNAs with no vector backbone is approximately one and one half times higher than traditional plasmids" (p. 4). (Holycow comment: Oh my God. Am I right? This means two and a half times more effective!)(I need help here. Is this a claim of 50 percent higher or a hundred and fifty percent higher -which is two and a half time higher?)
6. Work on delivery to cells inside the body, I guess, that are neither viruses nor bacteria, is continuing with a greater focus on non-viral delivery methods due to safety concerns (pp. 4, 5).
7. Cancer program. Lung and melanoma of particular note in my interpretation. Lung is a biggie accounting for more than half of all cancers (from my recollection). They note ominously that all these listed cancers can end up in the lungs before you die (page 4 top). Melanoma is what this Dr. Stein is working on at Albert Einstein (p. 5). My crass interpretation of the fact that this man has agreed to increase his involvement with Cytogenix by agreeing to serve on the Board is a sign that this important research is going well. (Melanoma is a small-fry in the picture of yearly cancer deaths, accounting for some 8000 a year - but still important of course). And now, back out into that terrible heat.
AI
